本文選題：茶堿緩釋干混懸劑 + 生物等效性��； 參考：《中國醫(yī)藥工業(yè)雜志》2015年03期

【摘要】：研究茶堿緩釋干混懸劑(受試制劑)和茶堿緩釋片(參比制劑)在Beagle犬體內(nèi)的藥動(dòng)學(xué)和生物等效性。進(jìn)行雙周期交叉試驗(yàn),每條Beagle犬單次口服給予受試或參比制劑200 mg。建立了HPLC法測定Beagle犬血漿中的茶堿,用非房室模型分析得到參比制劑與受試制劑的主要藥動(dòng)學(xué)參數(shù),分別為cmax(9.75±1.91)和(8.94±0.86)μg/ml,tmax(2.58±0.92)和(2.67±0.82)h,AUC0→t(76.59±9.51)和(75.22±15.06)μg·ml-1·h,AUC0→∞(79.55±9.86)和(77.08±13.44)μg·ml-1·h,t1/2(3.19±0.95)和(3.18±0.63)h,MRT(5.80±0.55)和(6.08±0.83)h。統(tǒng)計(jì)分析結(jié)果表明茶堿緩釋干混懸劑與市售茶堿緩釋片生物等效。
[Abstract]:The pharmacokinetics and bioequivalence of theophylline slow-release dry suspension (test preparation) and theophylline sustained-release tablets (reference preparation) in Beagle dogs were studied. Two-cycle cross-over test was conducted. Each Beagle dog was given a single oral dose of 200 mg. 寤虹珛浜咹PLC娉曟祴瀹欱eagle鐘嫻嗕腑鐨勮尪紕，

本文編號(hào)：1883717